Gene transfer for activation of CMV specific T cells.
Cytomegalovirus (CMV) is responsible for significant morbidity and mortality in immunocompromised patients undergoing allogeneic hematopoietic stem cell transplantation. The limitations of antiviral drugs and a better understanding of the cellular immune response to CMV has lead to the development of alternative therapies that restore host cellular immunity to CMV. Infusion of donor T lymphocytes results in variable protection against CMV but a high incidence of graft-versus-host disease in the allogeneic setting. To prevent this complication and further improve anti-CMV immune response, several groups have developed new approaches, such as the introduction of a suicide gene to control alloreactivity against the host or the selective activation of CMV-specific T cells by antigen-presenting cells expressing CMV antigens introduced by gene transfer. Depending on the target cells and the strategy chosen, adenovirus, retrovirus or poxviruses derived vectors are used for gene transfer. The protocols as well as the preclinical and clinical results obtained in the field of anti-CMV immunotherapy using gene transfer are reported and discussed.
André-Schmutz
Isabelle
I
INSERM U429 (I.A-S., M.C-C.), Hopital Necker-Enfants Malades, Paris, France. andre-schmutz@necker.fr
Dal Cortivo
Liliane
L
Hamel
Yamina
Y
Cavazzana-Calvo
Marina
M
D000938:Antigen-Presenting Cells / Q000276:immunology; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology / Q000821:virology; D003587:Cytomegalovirus / Q000235:genetics / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000517:prevention & control / Q000628:therapy*; D003713:Dendritic Cells / Q000276:immunology; D041722:Genes, Transgenic, Suicide / Q000276:immunology; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D006086:Graft vs Host Disease / Q000517:prevention & control / Q000628:therapy; D004854:Herpesvirus 4, Human / Q000235:genetics; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D007963:Leukocytes, Mononuclear / Q000276:immunology; D010750:Phosphoproteins / Q000235:genetics / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D013937:Thymidine Kinase / Q000235:genetics; D014162:Transfection; D014611:Vaccination; D014763:Viral Matrix Proteins / Q000235:genetics / Q000276:immunology
D000956:Antigens, Viral; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa; D013937:Thymidine Kinase